source
- Lilly beats forecasts while Novo Nordisk misses sales and trial targetsEli Lilly reported second-quarter revenue of nearly $23 billion, up 48% year-over-year, easily surpassing analysts’ $20.6 billion estimate. The boost came from continued strength of its tirzepatide…
- Expedition Therapeutics secures $115M Series B to advance China-origin COPD drugExpedition Therapeutics, a biotech that licenses drugs from Chinese firms, announced a $115 million Series B financing that will fund mid-stage testing of its experimental COPD candidate. The fund…